Scientists Probe Genetics Of Brain VulnerabilityJanuary 10, 2003Researchers at the University of Edinburgh are investigating why people with a specific genetic makeup are more likely to develop brain disease and less likely to make a good recovery from head injury. The study has important implications for those with the particular brain protein who choose to take part in potentially dangerous contact sports such as ice hockey, football, rugby and boxing. One third of the population carries the specific form of brain protein (APOE-4) which is known to be associated with higher danger both of developing dementia and also of recovering less well from a head injury. At present, there are few effective treatments for brain injury and damage and there is poor understanding of the underlying mechanisms involved. The Edinburgh scientists aim to understand why people with APOE-4 protein are more vulnerable to the effects of brain injury and diseases. Dr Karen Horsburgh of the Centre for Neuroscience Research, said: "In the United Kingdom more than 100,000 people are admitted to hospital each year with head injury, and there are an estimated 100,000 head injury survivors with persistent handicap-many of these are young people. A history of previous head injury is also a major risk factor in developing Alzheimer's disease, the cause of the majority of cases of dementia. Alzheimer's affects 5% of the population over the age of 65 and 20% of those aged over 80, so it is seen as a growing problem in an ageing society. "Brain cells slowly deteriorate and die as part of normal ageing but this process is accelerated in Alzheimer's disease and also as a result of a brain injury such as stroke or head injury. Those with APOE-4 have a greater risk than normal of developing dementia. We also believe that young people carrying APOE-4 will make a worse recovery from head injury, perhaps because of a reduced capacity for brain repair. This research therefore has implications for doctors treating patients with brain injury, stroke or dementia and strategies for patient care." Dr Horsburgh and her colleague Professor James McCulloch will spend five years studying the links between APOE-4 and brain injury and disease, supported by a Wellcome Trust grant of £348, 000. Edinburgh, University of |
|||||||||||||||||||||
| Related Alzheimer Disease Current Events and Alzheimer Disease News Articles Delirium in hospitalized adults: Situation critical, no relief available Every year as many as seven million adults in the United States experience delirium during hospitalization. New data demonstrate potential for early detection of Alzheimer's disease Data published in the June issue of the Journal of Alzheimer's Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer's disease. Another McGill/JGH breakthrough opens door to early Alzheimer's diagnosis A new diagnostic technique which may greatly simplify the detection of Alzheimer's disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital (JGH). Measuring brain atrophy in patients with mild cognitive impairment Scientists at the University of California, San Diego School of Medicine have shown that a fully automated procedure called Volumetric MRI - which measures the "memory centers" of the brain and compares them to expected size - is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease. Commonly used medications may produce cognitive impairment in older adults Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults. Commonly used ulcer drugs may offer treatment potential in Alzheimer's disease In a new study, published in the May issue of Elsevier's Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug. New test for mysterious metabolic diseases developed at Stanford/Packard Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism. Recalibrating 'fight or flight' A Canadian/U.S. research team has reported a novel approach to stimulating recovery from chronic stress disorders. Details of the therapeutic model, which exploits the natural dynamics of the body's "fight or flight" system, are published January 23 in the open-access journal PLoS Computational Biology Vitamin B does not slow cognitive decline in Alzheimer's A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease. Protecting patient privacy the new fashioned way Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act. More Alzheimer Disease Current Events and Alzheimer Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||